Clinical Trial Detail

NCT ID NCT02839681
Title Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

lung adenocarcinoma

Therapies

Anetumab ravtansine

Age Groups: adult senior

Additional content available in CKB BOOST